BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 996 filers reported holding BAXTER INTL INC in Q2 2015. The put-call ratio across all filers is 0.74 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2015 | $132,514,000 | -18.4% | 1,894,945 | -20.1% | 0.11% | -23.8% |
| Q1 2015 | $162,485,000 | -31.9% | 2,372,043 | -27.1% | 0.14% | -39.4% |
| Q4 2014 | $238,453,000 | +10.2% | 3,253,550 | +7.9% | 0.24% | -2.1% |
| Q3 2014 | $216,378,000 | +13.8% | 3,014,876 | +14.6% | 0.24% | +5.7% |
| Q2 2014 | $190,187,000 | +0.0% | 2,630,530 | +1.8% | 0.23% | -8.1% |
| Q1 2014 | $190,157,000 | +83.6% | 2,584,358 | +73.5% | 0.25% | +78.4% |
| Q4 2013 | $103,587,000 | +24.1% | 1,489,395 | +17.2% | 0.14% | +13.9% |
| Q3 2013 | $83,452,000 | +4.0% | 1,270,395 | +9.7% | 0.12% | -1.6% |
| Q2 2013 | $80,222,000 | – | 1,158,110 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |